Current COVID-19 vaccines effectively reduce severe disease and death but less optimally prevent infection. This study developed an intranasal vaccine (DelNS1-RBD4N-DAF) using a live-attenuated influenza virus expressing the SARS-CoV-2 receptor-binding domain (RBD). In mice and hamsters, DelNS1-RBD4N-DAF induced high neutralizing antibody levels and robust T cell responses. Crucially, intranasal DelNS1-RBD4N-DAF, unlike intramuscular mRNA vaccine (BNT162b2), prevented SARS-CoV-2 replication (including Delta and Omicron BA.2 variants) in respiratory tissues. This LAIV warrants further human evaluation for SARS-CoV-2 transmission control and as a dual-function influenza/COVID-19 vaccine.
Publisher
Nature Communications
Published On
Apr 12, 2023
Authors
Shaofeng Deng, Ying Liu, Rachel Chun-Yee Tam, Pin Chen, Anna Jinxia Zhang, Bobo Wing-Yee Mok, Teng Long, Anja Kukic, Runhong Zhou, Haoran Xu, Wenjun Song, Jasper Fuk-Woo Chan, Kelvin Kai-Wang To, Zhiwei Chen, Kwok-Yung Yuen, Pui Wang, Honglin Chen
Tags
COVID-19
intranasal vaccine
DelNS1-RBD4N-DAF
SARS-CoV-2
immune response
live-attenuated influenza virus
vaccine efficacy
Related Publications
Explore these studies to deepen your understanding of the subject.